<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; unbranded</title>
	<atom:link href="http://www.tapanray.in/tag/unbranded/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Draft Pharma Policy 2017 And Branded Generics</title>
		<link>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=draft-pharma-policy-2017-and-branded-generics</link>
		<comments>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/#comments</comments>
		<pubDate>Sun, 27 Aug 2017 23:55:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Bioavailability]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GLP]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unbranded]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[WOW]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8385</guid>
		<description><![CDATA[In its first reading, the 18-page draft Pharma Policy, 2017 gives me a sense that the Government has followed the much-desired principle of ‘walk the talk’, especially in some key areas. One such space is what Prime Minister Modi distinctly &#8230; <a href="http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
